论文信息 - Phase I First-in-Class Trial of MCARH109, a G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D) Targeted CAR T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma - 字舞流文

Phase I First-in-Class Trial of MCARH109, a G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D) Targeted CAR T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma

S. Devlin | A. Lesokhin | V. Bermudez | A. Dogan | R. Brentjens | B. Sénéchal | O. Landgren | N. Korde | S. Mailankody | M. Hultcrantz | S. Giralt | H. Landau | I. Rivière | Eric L. Smith | D. Sikder | Xiuyan Wang | U. Shah | H. Hassoun | M. Roshal | M. Scordo | Jae H. Park | C. Tan | T. Purdon | C. Diamonte | G. Shah | D. Chung | Jonathan Landa | J. Morgan | K. Hosszu | Lisa Fitzgerald | P. Kane | D. Frias | Patrick Grant | B. Senechal